| ABSTRACT Objective:To analyze and discuss the treatment effect and economic effect of moxifloxacin sequential therapy for the treatment of bronchialpneumonia.Methods:A total of 57 patients which were confirmed by sputum culture with bronchopneumonia caused by bacteria in our hospital from January 2012 to January 2013 were selected and randomly divided into two groups. The observation group 29 cases used moxifloxacin sequential therapy as adjuvant therapy on the basis of conventional treatment, and 28 cases for control group were attached to an intravenous drip with moxifloxacin 400mg each time and once a day on the basis of conventional treatment. The clinical efficacy, improvement of symptoms, length of stay and adverse reaction between two groups were compared. The cost and effect of two kinds of treatments with moxifloxacin were compared and evaluated. Results: The clinical total effective rate of observation group reached 96.55%, and 92.86% in the control group with no statistically significant difference(P>0.05). The time for normal body temperature, normal chest films, stopping cough and average stay in the observation group was shorter than the control group (P<0.05), and there was no statistically significant difference in hospital time (P>0.05).Moreover, the cost of moxifloxacin sequential therapy for the treatment of bronchial pneumonia was lower than the conventionaltreatment. Conclusion:The moxifloxacin sequential therapy has the same effect on the treatment of bronchial pneumoniawith ordinary therapy. Besides, the moxifloxacin sequential therapy has a lower cost and less incidence of adverse reactions. |
